Skip to main content
SpringerLink
Log in

The in vitro activity of N-formimidoyl thienamycin compared with other broad-spectrum cephalosporins and with clindamycin and metronidazole

Vergleichende In vitro-Aktivität von N-formimidoyl-Thienamycin mit Breitspektrum-Cephalosporinen sowie mit Clindamycin und Metronidazol

  • Originalia
  • Published:
Infection Aims and scope Submit manuscript

Summary

N-formimidoyl thienamycin is a new semisynthetic beta-lactam antibiotic still awaiting clinical trials. We have investigated thein vitro activity of N-formimidoyl thienamycin against 413 fresh clinical isolates and compared it to other new beta-lactam drugs and to clindamycin and metronidazole in the agar dilution test. All coliforms were inhibited by ≤1 mg/l and no member of theProteus group was resistant to more than 8 mg/l of N-formimidoyl thienamycin. The MICs forPseudomonas aeruginosa were ≤4 mg/l. Beta-haemolytic streptococci, pneumococci and staphylococci, including methicillin-resistant strains, were all inhibited by 0.125 mg/l or less.Streptococcus faecalis strains were all susceptible to ≤2 mg/l. N-formimidoyl thienamycin was highly active against the anaerobes tested. N-formimidoyl thienamycin exhibited bactericidal activity, and changes in inoculum size had little effect on the MICs. This data has shown that N-formimidoyl thienamycin has excellent antibacterial activity and an unusually broad spectrum of activity.

Zusammenfassung

N-formimidoyl-Thienamycin stellt ein neues, semisynthetisches Betalaktam-Antibiotikum dar, dessen klinischer Wert noch nicht erprobt ist. Die antibakterielle Aktivität dieser Substanz wurdein vitro an 413 frisch isolierten Bakterienstämmen untersucht und mit der Aktivität von neuen Betalaktam-Antibiotika sowie mit der von Clindamycin und Metronidazol verglichen. Testmethode war der Agardilutionstest. Alle coliformen Bakterien wurden durch ≤1 mg/l, alleProteus-Stämme durch ≤8 mg/l N-formimidoyl-Thienamycin gehemmt. Die MHK-Werte gegenPseudomonas aeruginosa betrugen ≤4 mg/l. Betahämolytische Streptokokken, Pneumokokken und Staphylokokken einschließlich Methicillin-resistenter Stämme wurden durch Konzentrationen von 0.125 mg/l oder kleiner inhibiert. AlleStreptococcus-faecalis-Stämme waren gegen ≤ 2 mg/l empfindlich. N-f-Thienamycin erwies sich als hoch aktiv gegen Anaerobier. N-f-Thienamycin wirkte bakterizid. Die Größe des Inokulums hatte kaum Einfluß auf die Höhe der Hemmwerte. Die Resultate zeigten, daß N-f-Thienamycin hohe antibakterielle Aktivität und ein ungewöhnlich breites Wirkungsspektrum aufweist.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

Literature

  1. Kahan, J. S., Kahan, F. M., Goegelman, R., Currie, S. A., Jackson, M., Stapley, E. O., Miller, T. W., Miller, A. K., Hendlin, D., Mochales, S., Hernandez, S., Woodruff, H. B., Birnbaum, J. Thienamycin, a new beta-lactam antibiotic. I. Discovery, taxonomy, isolation and physical properties. J. Antibiot. 32 (1979) 1–12.

    Google Scholar 

  2. Albers-Schönberg, G., Arison, B. H., Hensens, O. D., Hirschfield, J., Hoogsteen, K., Kaczka, E. A., Rhodes, R. E., Kahan, J. S., Kahan, F. M., Ratcliffe, R. W., Walton, E., Ruswinkle, L. J., Morin, R. B., Christensen, B. G. Structure and absolute configuration of thienamycin. J. Am. Chem. Soc. 100 (1978) 6491–6498.

    Google Scholar 

  3. Tally, F. P., Jacobus, N. V., Gorbach, S. L. In vitro activity of thienamycin. Antimicrob. Agents Chemother. 14 (1978) 436–438.

    Google Scholar 

  4. Weaver, S. S., Bodey, G. P., LeBlanc, B. M. Thienamycin: New beta-lactam antibiotic with potent broad-spectrum activity. Antimicrob. Agents Chemother. 15 (1979) 518–521.

    Google Scholar 

  5. Wildonger, K. J., Leanza, W. J., Miller, T. W., Christensen, B. G.: Program Abstracts, 19th Interscience Conference on Antimicrobial Agents and Chemotherapy, Boston, MA 1979, Abstr. 232.

  6. Toda, M., Sato, K., Nakazawa, H., Inoue, M., Mitsuhashi, S. Effect of N-formimidoyl thienamycin (MKO787) on beta-lactamases and activity against beta-lactamase-producing strains. Antimicrob. Agents Chemother. 18 (1980) 837–838.

    Google Scholar 

  7. Richmond, M. H. The semisynthetic thienamycin derivative (MKO787) and its properties with respect to a range of beta-lactamases from clinically relevant bacterial species. J. Antimicrob. Chemother. 7 (1981) 279–285.

    Google Scholar 

  8. Kayser, F. H. Microbiological studies on cefoperazone. Clin. Ther., Special Issue 3 (1980) 24–33.

    Google Scholar 

  9. Kropp, H., Sundelof, J. G., Kahan, J. S., Kahan, F. M., Birnbaum, J. MKO787 (N-formimidoyl thienamycin): Evaluation ofin vitro andin vivo activities. Antimicrob. Agents Chemother. 17 (1980) 993–1000.

    Google Scholar 

  10. Kesado, T., Hashizume, T., Asahi, Y. Antibacterial activity of a new stabilized thienamycin, N-formimidoyl thienamycin, in comparison with other antibiotics. Antimicrob. Agents Chemother. 17 (1980) 912–917.

    Google Scholar 

  11. Horadam, V. W., Smilack, J. D., Montgomery, C. L., Werringloer, J. In vitro activity of N-formimidoyl thienamycin (MKO787), a crystalline derivative of thienamycin. Antimicrob. Agents Chemother. 18 (1980) 557–561.

    Google Scholar 

  12. Tally, F. P., Jacobus, N. V., Gorbach, S. L. In vitro activity of N-formimidoyl thienamycin (MKO787). Antimicrob. Agents Chemother. 18 (1980) 642–644.

    Google Scholar 

  13. Livingston, W. K., Elliott, A. M., Cobbs, C. G. In vitro activity of N-formimidoyl thienamycin (MKO787) against resistant strains ofPseudomonas aeruginosa, Staphylococcus epidermidis, Serratia marcescens, andEnterococcus spp. Antimicrob. Agents Chemother. 19 (1981) 114–116.

    Google Scholar 

  14. Shadomy, S., May, R. S. N-formimidoyl thienamycin (MKO787):In vitro study. Antimicrob. Agents Chemother. 19 (1981) 201–204.

    Google Scholar 

  15. Brown, J. E., Del Bene, V. E., Collins, C. D. In vitro activity of N-formimidoyl thienamycin, moxalactam and other new beta-lactam agents againstBacteroides fragilis: Contribution of beta-lactamase to resistance. Antimicrob. Agents Chemother. 19 (1981) 248–252.

    Google Scholar 

  16. Verbist, L., Verhaegen, J. In vitro activity of N-formimidoyl thienamycin in comparison with cefotaxime, moxalactam and ceftazidime. Antimicrob. Agents Chemother. 19 (1981) 402–406.

    Google Scholar 

  17. Tutlane, V. A., McCloskey, R. V., Trent, J. A. In vitro comparison of N-formimidoyl thienamycin, piperacillin, cefotaxime and cefoperazone. Antimicrob. Agents Chemother. 20 (1981) 140–143.

    Google Scholar 

  18. Wise, R., Andrews, J. M., Patel, N. N-formimidoyl thienamycin, a novel beta-lactam: anin vitro comparison with other beta-lactam antibiotics. J. Antimicrob. Chemother. 7 (1981) 521–529.

    Google Scholar 

  19. Hanslo, D., King, A., Shannon, K., Warren, C., Phillips, I. N-formimidoyl thienamycin (MKO787):in vitro antibacterial activity and susceptibility to beta-lactamases compared with that of cefotaxime, moxalactam and other beta-lactam antibiotics. J. Antimicrob. Chemother. 7 (1981) 607–617.

    Google Scholar 

  20. O'Callaghan, C. H., Morris, A., Kirby, S. M., Shingler, A. H. Novel method for detection of betalactamases by using a chromogenic cephalosporin substrate. Antimicrob. Agents Chemother. 1 (1972) 283–288.

    Google Scholar 

  21. Reimer, G. L., Stratton, C. W., Reller, L. B. Minimum inhibitory and bactericidal concentrations of 44 antimicrobial agents against three standard control strains in broth with and without human serum. Antimicrob. Agents Chemother. 19 (1981) 1050–1055.

    Google Scholar 

  22. Washington II, J. A., Sutter, V. L. Dilution susceptibility test: Agar and macro-broth dilution procedures: In:Lennette, E. H., Balows, A., Hausler Jr, W. J., Truant, J. P. (eds.): Manual of clinical microbiology. American Society for Microbiology, Washington, D. C. 1980, pp. 453–458.

    Google Scholar 

  23. Gavan, T. L., Barry, A. L. Microdilution test procedures: In:Lennette, E. H., Balows, A., Hausler Jr, W. J., Truant, J. P. (eds.): Manual of clinical microbiology. American Society for Microbiology, Washington, D. C. 1980, pp. 459–462.

    Google Scholar 

  24. Sutter, V. L., Barry, A. L., Wilkins, T. D., Zabransky, R. J. Collaborative evaluation of a proposed reference dilution method of susceptibility testing of anaerobic bacteria. Antimicrob. Agents Chemother. 16 (1979) 495–502.

    Google Scholar 

  25. Rotilie, C. A., Fass, R. J., Prior, R. B., Perkins, R. L. Microdilution technique for antimicrobial susceptibility testing of anaerobic bacteria. Antimicrob. Agents Chemother. 7 (1975) 311–315.

    Google Scholar 

  26. Corrado, M. L., Cherubin, C. E., Shulman, M., Moen, J., Jhagroo, M. The activity of gentamicin and N-formimidoyl thienamycin (MKO787) onPseudomonas aeruginosa at pH 7.4 and 7.0. J. Antimicrob. Chemother. 7 (1981) 677–680.

    Google Scholar 

  27. Shanson, D. C., Kensit, J. G., Duke, R. Outbreak of hospital infections with a strain ofStaphylococcus aureus resistant to gentamicin and methicillin. Lancet II (1976) 1347–1348.

    Google Scholar 

  28. Kayser, F. H. Die Resistenz methicillinresistenter Staphylokokken gegenüber neuen Cephalosporin-Antibiotika. Infection 8 (1980) 165–170.

    Google Scholar 

  29. Crossley, K., Loesch, D., Landesman, B., Mead, K., Chern, M., Strate, R. An outbreak of infections caused byStaphylococcus aureus resistant to methicillin and aminoglycosides. I. Cinical studies. J. Infect. Dis. 139 (1979) 273–287.

    Google Scholar 

  30. Amirak, I. D., Li, A. K. C., Williams, R. J., Noone, P. A fatal infection caused by methicillin-resistantStaphylococcus aureus acquiring resistance to gentamicin and fusidic acid during therapy. J. Infect. 3 (1981) 50–58.

    Google Scholar 

  31. Graham, D. R., Correa-Villasenor, A., Anderson, R. L., Vollman, J. H., Baine, W. B. Epidemic neonatal gentamicin-methicillin-resistantStaphylococcus aureus infection associated with nonspecific topical use of gentamicin. J. Pediatr. 97 (1980) 972–978.

    Google Scholar 

  32. Corrado, M. L., Landesman, S. H., Cherubin, C. E. Influence of inoculum size on activity of cefoperazone, cefotaxime, moxalactam, piperacillin and N-formimidoyl thienamycin (MKO787) againstPseudomonas aeruginosa. Antimicrob. Agents Chemother. 18 (1980) 893–896.

    Google Scholar 

  33. Kayser, F. H., Huf, E., Homberger, F. The microbiology of cefoperazone. Infection 9 Suppl. 1 (1981) S6–S12.

    Google Scholar 

  34. Kayser, F. H., Morenzoni, G., Homberger, F. Activity of cefoperazone against ampicillin-resistant bacteria in agar and broth dilution tests. Antimicrob. Agents Chemother. 22 (1982) 15–22.

    Google Scholar 

  35. Kropp, H., Sundeloff, J. G., Hajdu, R., Kahan, F. M.: Metabolism of thienamycin and related carbapenem antibiotics by the renal dipeptidase: dehydropeptidase-I. Abstracts, 20th Interscience Conference on Antimicrobial Agents and Chemotherapy, New Orleans, LA, American Society of Microbiology, 1980.

Download references

Author information

Authors and Affiliations

  1. Institut für Medizinische Mikrobiologie der Universität, Gloriastraße 32, Postfach, GH-8028, Zürich

    G. Tischhauser &  F. H. Kayser

Authors
  1. G. Tischhauser
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. F. H. Kayser
    View author publications

    You can also search for this author in PubMed Google Scholar

Rights and permissions

Reprints and permissions

About this article

Cite this article

Tischhauser, G., Kayser, F.H. The in vitro activity of N-formimidoyl thienamycin compared with other broad-spectrum cephalosporins and with clindamycin and metronidazole. Infection 11, 219–226 (1983). https://doi.org/10.1007/BF01641202

Download citation

  • Received:

  • Accepted:

  • Issue Date:

  • DOI: https://doi.org/10.1007/BF01641202

Keywords

Search

Navigation